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Abstract: 
Aims: The aim of the present study was to explore how risk factors and medication influence 
clinical presentation and mortality in coronary heart disease (CHD) and to explain how much of 
the decrease in CHD mortality in Sweden that could be attributed to medical and surgical 
treatments, and how much to changes in cardiovascular risk factors.  
Subjects and methods: We included 781 consecutive patients with a first acute myocardial 
infarction (AMI) during the period 1994 to 2002, to investigate trends in the use of lipid-lowering 
treatment, and changes in serum lipids. The second part of the study is based on 93,416 
consecutive patients aged 25 to 84 years from RIKS-HIA, a national quality of care register that 
includes all patients admitted to CCUs in Sweden and admitted to hospital between 1996 and 
2004 with a first AMI. The IMPACT mortality model was used to combine and analyze data on 
uptake and effectiveness of cardiological treatments and risk factor trends in Sweden, to 
investigate the relative contributions of these factors on the decline in CHD mortality in Sweden. 
The main data sources were official statistics, national quality of care registers, published trials 
and meta-analyses and national population surveys.  
Results: In the single-centre study almost all patients under 65 years of age with a first AMI were 
treated with lipid-lowering drugs in 2002. Still, target levels for serum cholesterol were not met in 
a substantial number of patients. In the RIKS-HIA population, more than 50% of younger patients 
presenting with STEMI were smokers at the time of hospitalization. After adjustments, smoking 
was found to be an independent determinant for presenting with STEMI compared to non-STEMI. 
In addition, use of aspirin, β-blocker, ACE-inhibitor and statin prior to hospitalization were all 
associated with lower odds of presenting with STEMI compared to non-STEMI in both men and 
women.  Between 1986 and 2002, CHD mortality rates in Sweden decreased by 53.4% in men 
and 52.0% in women aged 25 to 84 years. This resulted in 13,180 fewer deaths in 2002. By using 
the IMPACT model approximately 36% of this decrease could be attributed to treatments in 
individuals and 55% to population risk factor reductions. Adverse trends were seen for diabetes 
and overweight.  
Conclusions: Despite a marked increase in lipid-lowering drug treatment, current target levels of 
<4.5 mmol/l for serum cholesterol are not met in a significant proportion of post-AMI 
patients.Tobacco smoking is a major determinant for presenting with STEMI, indicating that 
smoking is one of the major risk factors for presenting with more severe AMIs. Previous 
medication with aspirin, β-blocker, ACE inhibitor or statin is associated with substantially lower 
risk of presenting with STEMI. More than half of the CHD mortality decrease between 1986 and 
2002 was attributable to reductions in major risk factors, mainly a large decrease in serum 
cholesterol, emphasizing the value of a comprehensive strategy that promotes primary prevention 
and evidence-based medical treatments, especially secondary prevention. 
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